Gastro Education 2018
Journal of Clinical Gastroenterology and Hepatology
ISSN: 2575-7733
Page 58
September 06-07, 2018
London, UK
14
th
International Conference on
Gastro Education
Esophageal Varices:
Esophageal varices are dilated submucosal
distal esophageal veins connecting the portal and systemic
circulations. This happens due to portal hypertension (most
commonly a result of cirrhosis), resistance to portal blood flow,
and increased portal venous blood inflow. The most common
fatal complication of cirrhosis is variceal rupture; the severity of
liver disease correlates with the presence of varices and risk of
bleeding.
Bleeding esophageal varices:
No single treatment for bleeding
esophageal varices is appropriate for all patients and situations.
An algorithm for management of the patient with acute bleeding
is presented in this article. The options for long-term, definitive
therapy and the criteria for selection of each are discussed.
Pathophysiology and management of esophageal varices:
Esophageal varices are one of the most common and severe
complications of chronic liver disease. New aspects in
epidemiology,pathogenesis,andtreatmentofvaricesarereviewed.
Sclerotherapy is the first-line treatment for acute hemorrhage.
Prevention of first or recurrent bleeding is still unsatisfactory.
β-Blockers are slightly superior to sclerotherapy with regard to
prophylaxis of first bleeding. β-Blockers or sclerotherapy may be
used for prophylaxis of recurrent bleeding. However, prophylactic
treatment regimens do not have a major impact on survival.
Combination treatment, new drugs, or new devices may help to
improve the efficacy of prophylactic measures.
Endoscopic Therapy for Esophageal Varices:
Among therapeutic
endoscopic options for esophageal varices (EV), endoscopic
variceal ligation (EVL) has proven more effectiveness and
safety compared with endoscopic sclerotherapy and is currently
considered as the first choice. In acute EV bleeding, vasoactive
therapy(eitherwithterlipressinorsomatostatin)priortoendoscopy
improves outcomes; moreover, antibiotic prophylaxis has to
be generally adopted. Variceal glue injection (cyanoacrylates)
seems to be effective in the treatment of esophageal as well as in
gastric varices. Prevention of rebleeding can be provided both by
EVL alone or combined with non-selective β-blockers. Moreover,
EVL can be adopted for primary prophylaxis, with no differences
in mortality compared with drugs, in subjects with large varices
and unfit for a β-blocker regimen.
A meta‐analysis of endoscopic variceal ligation for primary
prophylaxis of esophageal variceal bleeding:
Despite publication
of several randomized trials of prophylactic variceal ligation, the
effect on bleeding‐related outcomes is unclear. We performed a
meta‐analysis of the trials, as identified by electronic database
searchingandcross‐referencing.Bothinvestigatorsindependently
applied inclusion and exclusion criteria, and abstracted data
from each trial. Standard meta‐analytic techniques were used
to compute relative risks and the number needed to treat (NNT)
for first variceal bleed, bleed‐related mortality, and all‐cause
mortality. Among601patients in5homogeneous trials comparing
prophylactic ligation with untreated controls, relative risks of first
variceal bleed, bleed‐related mortality, and all‐cause mortality
were 0.36 (0.26‐0.50), 0.20 (0.11‐0.39), and 0.55 (0.43‐0.71), with
respective NNTs of 4.1, 6.7, and 5.3. Among 283 subjects from
4 trials comparing ligation with β‐blocker therapy, the relative
risk of first variceal bleed was 0.48 (0.24‐0.96), with NNT of 13;
however, there was no effect on either bleed‐related mortality
(relative risk [RR], 0.61; confidence interval [CI], 0.20‐1.88) or all‐
cause mortality (RR, 0.95; CI, 0.56‐1.62). In conclusion, compared
with untreated controls, prophylactic ligation reduces the risks
of variceal bleeding and mortality. Compared with β‐blockers,
ligation reduces the risk for first variceal bleed but has no effect
on mortality. Prophylactic ligation should be considered for
patients with large esophageal varices who cannot tolerate β‐
blockers. Subsequent research should further compare ligation
and β‐blockers to determine the effect on mortality, and measure
ligation’s cost‐effectiveness.
dr.bsgill1@gmail.comPathophysiology and management of esophageal varices in
current practice
Balwant Singh Gill
Swami Ji Gastroenterology Center, Punjab, India
J Clin Gastroenterol Hepatol 2018, Volume 2
DOI: 10.21767/2575-7733-C2-006




